Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.
Onartuzumab was developed by
Genentech, Inc. It is undergoing clinical trials.
References
Monoclonal antibodies
{{antineoplastic-drug-stub